Certified by Founder
Lodge
OncoPep, Inc.
start up
United States
- Boston, Massachusetts
- 09/12/2021
- Series D
- $11,000,000
Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell focused technologies are designed to be used on their own or in combination with other immunotherapeutics.
- Industry Biotechnology Research
- Website https://oncopep.com/
- LinkedIn https://www.linkedin.com/company/oncopep-inc./